To summarize and analyze the clinical manifestation of conjunctival papilloma, its relationship with human papillomavirus (HPV) infection and the recurrence after the combination of operation and pharmacotherapy. A retrospective case series study. Analysis of 40 patients (41 eyes) with conjunctival papilloma treated at Peking Union Medical College Hospital from January 2008 to June 2018 was performed. All patients were given routine blood and urine, hepatitis B virus surface antigen, antibodies to hepatitis C virus, antibodies to human immunodeficiency virus and antibodies to testing, and HPV testing for the urethra epithelial tissue. Direct contact of the tumor with instruments was avoided during surgery, and freezing treatment was combined. HPV testing was performed for the resected conjunctival papilloma. Multiple medications were used after surgery. In 40 cases with 41 eyes, there were 22 males (23 eyes) and 18 females (18 eyes). A single tumor was seen in 27 eyes, and multiple tumors were seen in 14 eyes. Thirteen patients (13 eyes) older than 50 years old had pedicel-free papillpma, and 27 patients (28 eyes) aged from 12 to 40 years had pedicel-type papillpma. All cases were confirmed by pathology as conjunctival papilloma, of which 9 cases showed moderate to severe atypical hyperplasia on squamous cells. The HPV test was positive in 17 out of the 40 cases (42.5%) of conjunctival papilloma. Urine test results of 16 patients (40.0%) were positive for occult blood and showed that urinary white blood cell was elevated. Of the 40 patients, 33 were newly diagnosed and 7 had a relapse. The average follow-up time was (37.4±11.9) months after combined therapy and no recurrence was found in any patients. Conjunctival papilloma is usually observed in people aged from 20 to 40 years and older than 50 years, and it often occurs in one eye. Its main pathological feature is benign tumors of the papillary hyperplasia on the conjunctival epithelial tissue. Some patients have atypical hyperplasia of squamous cells. The cause of the disease may be related to the infection of HPV and the urinary tract. Combined treatment can reduce the recurrence rate of conjunctival papilloma. .
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3760/cma.j.issn.0412-4081.2019.05.011 | DOI Listing |
Cureus
November 2024
Ophthalmology, Hiroshima University, Hiroshima, JPN.
Cytotoxic anticancer drug solution eye drops can hinder the cell division of corneal basal cell division and corneal limbal epithelial stem cell migration. We discuss a case involving recurrent corneal epithelial erosions induced by 1% 5-fluorouracil (5-FU) solution eye drops. A 68-year-old male with conjunctival papilloma on his left eye underwent recurrences three times and additional tumor excision.
View Article and Find Full Text PDFArch Soc Esp Oftalmol (Engl Ed)
December 2024
Servicio de Oftalmología, Hospital Universitario La Paz, Madrid, Spain.
Purpose: To communicate the results and complications in a series of 17 proximal lacrimal pathway obstructions (PLPO) operated by conjunctivo-rhinostomy (CR) with Métaireau tube implantation.
Methods: Retrospective descriptive study including 16 patients (17 PLPO) operated with CR between April 2010 and June 2017. Surgeries were performed under general anesthesia.
Ophthalmol Sci
September 2024
Ophthalmology Consult Services Section, National Eye Institute, NIH, Bethesda, Maryland.
Objective: To investigate the effects of oral baricitinib on ocular surface disease (OSD) in patients with chronic graft-versus-host disease (cGVHD).
Design: Prospective phase 1 to 2 single institution trial.
Subjects: Eighteen patients with ocular graft-versus-host-disease (oGVHD) and systemic steroid-refractory cGVHD.
Cornea
November 2024
Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Purpose: We report a unique case of significant human papillomavirus-associated conjunctival papillomas and severe corneal ulceration leading to corneal perforation in a patient treated with dupilumab for atopic dermatitis.
Methods: This study is a case report and literature review of severe corneal side effects related to dupilumab.
Results: A 27-year-old man with severe atopic dermatitis and no ocular history was administered dupilumab 300 mg via subcutaneous injections every 2 weeks with an excellent response.
Can J Ophthalmol
August 2024
Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!